BP
EW icon

Ballentine Partners’s Edwards Lifesciences EW Stock Holding History

Ballentine Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$577K Buy
6,378
+127
+2% +$10.6K 0.01% 519
2026
Q1 		$501K Buy
6,251
+348
+6% +$28.7K 0.01% 531
2025
Q4 		$503K Sell
5,903
-174
-3% -$14.3K 0.01% 499
2025
Q3 		$473K Buy
6,077
+5
+0.1% +$391 0.01% 526
2025
Q2 		$475K Buy
6,072
+963
+19% +$71.8K 0.01% 500
2025
Q1 		$370K Sell
5,109
-375
-7% -$26.8K 0.01% 546
2024
Q4 		$406K Buy
5,484
+810
+17% +$56.7K 0.01% 492
2024
Q3 		$308K Sell
4,674
-670
-13% -$48.7K 0.01% 575
2024
Q2 		$494K Buy
5,344
+108
+2% +$9.56K 0.01% 410
2024
Q1 		$500K Buy
5,236
+984
+23% +$82.7K 0.01% 388
2023
Q4 		$324K Sell
4,252
-831
-16% -$57.8K 0.01% 480
2023
Q3 		$352K Sell
5,083
-570
-10% -$45.8K 0.01% 398
2023
Q2 		$533K Buy
5,653
+184
+3% +$16K 0.01% 302
2023
Q1 		$452K Buy
5,469
+563
+11% +$44.3K 0.01% 317
2022
Q4 		$366K Buy
4,906
+882
+22% +$68K 0.01% 336
2022
Q3 		$333K Buy
4,024
+991
+33% +$95.4K 0.01% 313
2022
Q2 		$288K Buy
3,033
+886
+41% +$91.7K 0.01% 333
2022
Q1 		$252K Buy
2,147
+280
+15% +$31.4K 0.01% 394
2021
Q4 		$242K Buy
1,867
+5
+0.3% +$583 0.01% 405
2021
Q3 		$211K Buy
+1,862
New +$213K 0.01% 388
2020
Q4 		– Sell
-4,447
Closed -$355K – 394
2020
Q3 		$355K Sell
4,447
-960
-18% -$74.9K 0.02% 259
2020
Q2 		$374K Buy
5,407
+67
+1% +$4.76K 0.02% 235
2020
Q1 		$335K Sell
5,340
-288
-5% -$20.8K 0.02% 235
2019
Q4 		$437K Hold
5,628
– – 0.02% 241
2019
Q3 		$412K Buy
5,628
+381
+7% +$26.8K 0.02% 238
2019
Q2 		$323K Buy
5,247
+1,431
+38% +$86.5K 0.02% 277
2019
Q1 		$243K Buy
+3,816
New +$218K 0.01% 284
2016
Q4 		– Sell
-6,474
Closed -$260K – 214
2016
Q3 		$260K Sell
6,474
-171
-3% -$6.44K 0.02% 152
2016
Q2 		$222K Buy
+6,645
New +$227K 0.02% 188

Other funds holding EW

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
FFM
Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Ballentine Partners's EW Position: Q2 2026 in Review

Ballentine Partners increased its Edwards Lifesciences (EW) stake by 2% in Q2 2026, buying an estimated $10.6K and bringing the position to 6,378 shares worth $577K. The position accounts for 0.01% of the portfolio, ranked #519.

Ballentine Partners first reported a position in EW in Q2 2016 and has held it in 29 quarters since. 240 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Ballentine Partners held 6,378 shares of Edwards Lifesciences worth $577K as of Q2 2026.
  • Ballentine Partners bought 127 Edwards Lifesciences shares in Q2 2026, an estimated $10.6K.
  • Edwards Lifesciences made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #519 holding.
  • Ballentine Partners first reported a position in Edwards Lifesciences in Q2 2016 and has held it in 29 quarters since.
  • 240 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.